Imatinib for the Adjuvant Treatment of Gastrointestinal Stromal Tumours (TA326) (review of TA196)

Technology Appraisal Guidance No. 326

Source: National Institute for Health and Care Excellence

NOTE: This guidance replaces Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (NICE technology appraisal guidance 196 issued in August 2010).

1. Guidance

1.1 Imatinib is recommended as an option as adjuvant treatment for up to 3 years for adults who are at high risk of relapse after surgery for KIT (CD117)-positive gastrointestinal stromal tumours, as defined by the Miettinen 2006 criteria[1] (based on tumour size, location and mitotic rate).

1.2 People currently receiving treatment initiated within the NHS with imatinib that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

[1]Miettinen M, Lasota J (2006) Gastrointestinal stromal tumours: review on morphology, molecular pathology, prognosis, and differential diagnosis. Archives of Pathology & Laboratory Medicine 130:1466–78

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

Imatinib for the adjuvant treatment of gastrointestinal stromal tumours.

Issue Date: November 2014

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more